Health TrialsbyHealthPanel

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

ConditionModerate to Severe Atopic Dermatitis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJiangsu vcare pharmaceutical technology co., LTD

About this trial

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • VC005 low dose group

    Drug

    VC005 low dose group repeat administration

  • VC005 high dose group

    Drug

    VC005 high dose group repeat administration

  • VC005 Placebo group

    Drug

    VC005 Placebo group repeat administration

Treatment groups

480 Participants
are divided into 3 treatment groups
Group A: VC005 low dose groupExperimental treatment 1 intervention
Group B: VC005 high dose groupExperimental treatment 1 intervention
Group C: VC005 placebo groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline at Week 16

Time frame
week 16

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jiangsu vcare pharmaceutical technology co., LTD

Lead sponsor

Source ClinicalTrials.gov
Apply now